Earlier on Thursday, drug maker Myrexis Inc. appointed Robert Lollini as the company’s permanent CEO. Lollini previously worked in the capacity of an interim president, CEO, and chief financial officer at Myrexis.
Lollini assumed his new role as CEO with immediate effect. He was further nominated to the board.
Subsequent to the resignation of former President and CEO Adrian N. Hobden in July, Lollini was designated to two positions on a provisional basis, further to his role as CFO.
Hobden continued to serve the company for 3 additional months in the capacity of a consultant to facilitate smooth transition of responsibilities to the new top executive.
Myrexis had appointed Lollini in February 2009 as the company’s CFO and treasurer.
Andrea Kendell who was also nominated by the Myrexis board as chief financial officer, served as vice president of finance and human resources since June 2010.
Salt-Lake-City-based drug maker develops medications to battle auto immune diseases and cancer.
After the announcement, Myrexis shares declined 13 cents, or 4.6 percent, to $2.70 in after-hours trading
They hiked to $2.83 during the regular session and are near their 52-week low of $2.65.